Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation

Rafael Holdings, Inc. (RFL) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/09/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Third Quarter Fiscal Year 2020 Results"
06/09/2020 10-Q Quarterly Report for the period ended April 30, 2020
05/26/2020 GN Rafael Pharmaceuticals to Present Phase 1 Data on CPI-613® (Devimistat) in Patients with Locally Advanced or Metastatic Pancreatic Cancer at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
05/07/2020 GN Rafael Pharmaceuticals Announces In Vivo Study to Evaluate the Effects of CPI-613® (Devimistat) in Combination with Azacitidine and Venetoclax on Acute Myeloid Leukemia Models
05/05/2020 GN Rafael Pharmaceuticals Enters into Research Collaboration with Roswell Park Comprehensive Cancer Center to Evaluate the Effects of CPI-613® (Devimistat) on Esophageal Cancer
04/28/2020 GN MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals' Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt's Lymphoma/Leukemia
04/23/2020 GN Rafael Pharmaceuticals Receives Approvals to Open Trial Sites in India and Canada for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
04/22/2020 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 32,711 shares @ $0
04/06/2020 4 JONAS HOWARD S (CEO) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Disposed of 787,163 shares @ $0
Disposed of 4,306,738 shares @ $0
03/26/2020 8-K Quarterly results
03/05/2020 10-Q Quarterly Report for the period ended January 31, 2020
03/05/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports Second Quarter Fiscal Year 2020 Results"
03/03/2020 GN Rafael Pharmaceuticals Appoints Sanjay Sehgal, Ph.D., to Chief Regulatory Affairs and Quality Assurance Officer
02/12/2020 SC 13G/A DIMENSIONAL FUND ADVISORS LP reports a 5.6% stake in RAFAEL HOLDINGS INC-CLASS B
02/04/2020 8-K Other Events
01/28/2020 4 ASH MENACHEM (President) has filed a Form 4 on Rafael Holdings, Inc.
Txns: Paid exercise price by delivering 5,238 shares @ $22.155, valued at $116k
01/21/2020 8-K Submission of Matters to a Vote of Security Holders
01/14/2020 GN Rafael Pharmaceuticals Crosses Halfway Enrollment Point in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer
01/13/2020 GN Rafael Pharmaceuticals to Present at 38th Annual J.P. Morgan Healthcare Conference
01/06/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/06/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/06/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/10/2019 8-K Quarterly results
12/09/2019 10-Q Quarterly Report for the period ended October 31, 2019
12/09/2019 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Rafael Holdings Reports First Quarter Fiscal Year 2020 Results"
12/03/2019 GN Data on Rafael Pharmaceuticals' CPI-613® (devimistat) in Patients with Relapsed Burkitt Lymphoma to be Presented at the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition
12/03/2019 GN Timothy Pardee, M.D., Ph.D., Co-Chief Medical Officer of Rafael Pharmaceuticals, to Present on CPI-613® (devimistat) in Relapsed/Refractory Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting & Expos
12/02/2019 25 Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities:
12/02/2019 GN Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt's Lymphoma/Leukemia to Massachusetts General Hospital in Boston
11/21/2019 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/18/2019 CERT Form CERT -
11/18/2019 8-A12B Form 8-A12B - Registration of securities [Section 12(b)]:
11/18/2019 8-K Quarterly results
10/30/2019 GN Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D.
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy